- Home
- DIAX vs ALMS Comparison
DIAX vs ALMS Comparison
Compare DIAX & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- ALMS
- Stock Information
- Founded
- DIAX 2005
- ALMS 2021
- Country
- DIAX United States
- ALMS United States
- Employees
- DIAX N/A
- ALMS N/A
- Industry
- DIAX Finance Companies
- ALMS
- Sector
- DIAX Finance
- ALMS
- Exchange
- DIAX Nasdaq
- ALMS NYSE
- Market Cap
- DIAX 552.4M
- ALMS 469.0M
- IPO Year
- DIAX N/A
- ALMS 2024
- Fundamental
- Price
- DIAX $15.52
- ALMS $7.41
- Analyst Decision
- DIAX
- ALMS Strong Buy
- Analyst Count
- DIAX 0
- ALMS 6
- Target Price
- DIAX N/A
- ALMS $29.60
- AVG Volume (30 Days)
- DIAX 96.6K
- ALMS 121.0K
- Earning Date
- DIAX 01-01-0001
- ALMS 02-15-2025
- Dividend Yield
- DIAX 7.93%
- ALMS N/A
- EPS Growth
- DIAX N/A
- ALMS N/A
- EPS
- DIAX N/A
- ALMS N/A
- Revenue
- DIAX N/A
- ALMS N/A
- Revenue This Year
- DIAX N/A
- ALMS N/A
- Revenue Next Year
- DIAX N/A
- ALMS N/A
- P/E Ratio
- DIAX N/A
- ALMS N/A
- Revenue Growth
- DIAX N/A
- ALMS N/A
- 52 Week Low
- DIAX $12.80
- ALMS $6.75
- 52 Week High
- DIAX $15.12
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- DIAX 63.15
- ALMS N/A
- Support Level
- DIAX $14.66
- ALMS N/A
- Resistance Level
- DIAX $15.17
- ALMS N/A
- Average True Range (ATR)
- DIAX 0.19
- ALMS 0.00
- MACD
- DIAX 0.06
- ALMS 0.00
- Stochastic Oscillator
- DIAX 100.00
- ALMS 0.00
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.